A prospective, multicenter, observational study of treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersen
Latest Information Update: 02 Sep 2021
Price :
$35 *
At a glance
- Drugs Nusinersen (Primary)
- Indications Spinal muscular atrophy
- Focus Therapeutic Use
- 02 Sep 2021 New trial record
- 01 Aug 2021 Results published in the European Journal of Neurology